Latest Content

Sylvester's Nicole Doell, MSN, RN, discusses how oncology nurses can support patients with breast cancer emotionally, from diagnosis to survivorship.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Daraxonrasib, tarlatamab, an mRNA melanoma therapy and ivonescimab led ESMO 2026. Tell us which findings you can act on now.

At an Oncology Nursing News roundtable, APPs discussed earlier lifileucel referral, IL-2 dosing, and toxicities that emerge after discharge.

Suzanne E. Barron, CRNP, explains how education, premedication, and pharmacy coordination streamline intravesical gene therapy treatment days.

Leslie Smith, DNP, shares how nurses at any hospital can work around limited time, heavy workloads, and slow approvals to get involved in research.

At an ONN Case-Based Roundtable, APPs discussed when to raise TIL therapy in melanoma and how to prepare patients for lymphodepletion and IL-2.

Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.

At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.

An NP-led roundtable reviewed 3L+ trial data in metastatic colorectal cancer and shared nursing strategies for myelosuppression, dosing, and goals.

New ANA guidance sets shared duties for nurses, leaders, and educators and favors restorative responses over zero-tolerance policies.

In TALAPRO-3, adding talazoparib to enzalutamide cut the risk of radiographic progression or death by 52%; anemia was the leading toxicity.

A Fox Chase intervention raised trial-naïve patients' understanding of placebo use and randomization; its effect on enrollment is still untested.